Journal of Literature Pharmacy Sciences

Tiyomersal Maruziyeti ve Otizm Spektrum Bozuklukları Arasındaki Olası İlişkinin Değerlendirilmesi
Evaluation of the Possible Association Between Thiomersal Exposure and Autism Spectrum Disorders
Selinay Başak ERDEMLİ KÖSEa,b, Aylin BALCIa , Anıl YİRÜNa,c, Pınar ERKEKOĞLUa,d
aHacettepe Üniversitesi Eczacılık Fakültesi, Farmasötik Toksikoloji ABD, Ankara, TÜRKİYE
bBurdur Mehmet Akif Ersoy Üniversitesi Fen-Edebiyat Fakültesi, Kimya Bölümü, Burdur, TÜRKİYE
c Çukurova Üniversitesi Eczacılık Fakültesi, Farmasötik Toksikoloji ABD, Adana, TÜRKİYE
dHacettepe Üniversitesi Aşı Enstitüsü, Aşı Teknolojileri ABD, Ankara, TÜRKİYE
J Lit Pharm Sci. 2020;9(3):304-18
doi: 10.5336/pharmsci.2020-73289
Article Language: TR
Full Text
ÖZET
 Tiyomersal aşılara antibakteriyel ve antifungal koruyucu olarak eklenen organik cıva bileşiğidir. Aşılar dışında birçok tıbbi ürün (immünglobulin preparatları, antitoksinler, deri preperatları, göz/kulak/burun damlaları, antiseptik merhemler, spreyler) ve kozmetik ürününde de kullanılmaktadır. Tiyomersalin molekül yapısının yaklaşık %50'sini cıva oluşturmaktadır ve organik cıva bileşiklerine maruziyetle otizm spektrum bozukluğu (OSB)'nun ortaya çıkabileceği literatürde yer almaktadır. Özellikle 2000'li yıllarda otizm olgularında görülen artışlar, tiyomersalin otizme neden olabileceğine dair endişeleri beraberinde getirmiştir. OSB, farklı genetik ve çevresel kökenlere sahip heterojen bir nörodavranışsal sorunlar bütünüdür. Bu patolojilerin karmaşıklığı ve kesin olarak bilinen diagnostik biyogöstergelerin bulunmaması nedeniyle OSB fenotipik davranış özellikleri ile tanımlanır. Çocukluk çağında, aşılama ile OSB arasındaki olası ilişki potansiyel bir çevresel neden olarak öne sürülmüştür. Cıva ve OSB arasındaki ilişkiye dair endişeler, ilk olarak 1990'larda başlamıştır. Şüpheler nedeniyle tiyomersal, günümüzde ülkemiz dâhil birçok ülkede çocukluk çağında kullanılan aşılardan tamamen kaldırılmıştır. Ancak ABD'de ve gelişmekte olan ülkelerde, bazı aşılar hâlâ tiyomersal içermektedir. Birçok düzenleyici kuruluş aşılama ile maruz kalınan cıva miktarının oldukça düşük olduğunu ve bu miktarın herhangi bir patolojik duruma neden olmayacağını defalarca ifade etse de günümüzde tiyomersal ile ilgili spekülasyonlar nedeniyle aşı kararsızlığı giderek artmaktadır. Ancak aşılama toplum sağlığının korunması için mutlaka gereklidir. Henüz kesinleşmemiş ve belki de hiç olmayan bu ilişki için çocukları aşılatmamak tüm toplumu büyük risk altına sokmaktadır. Bu derlemede, otizm, tiyomersal ve tiyomersal ile otizm arasındaki olası ilişki hakkında bilgi verilmesi amaçlanmıştır.

Anahtar Kelimeler: Otizm; tiyomersal; aşı; aşı kararsızlığı
ABSTRACT
 Thiomersal is an organic mercury compound used as antibacterial and antifungal preservative in vaccines. Other than vaccines, it is used in many medical products (immunoglobulin preparations, antitoxins, skin preparations; eye/ear/nose drops; antiseptic ointments, sprays) and cosmetics. The molecular structure of thiomersal consists of 50% mercury and literature suggests that exposure to organic mercury compunds may lead to autism spectrum disorders (ASD). Particularly in 2000s, concerns about thiomersal as a cause of autism has raised. ASD is a combination of heterogeneous neurobehavioral problems with different genetic and environmental origins. Because of the complexity of these pathologies and absence of a well-known diagnostic marker, ASD is characterized by phenotypic behavioral features. Interaction between childhood vaccination and ASD is put forward as a potential environmental cause. Concerns about the association between mercury and ASD first began in the 1990s. Because of doubts, thiomersal has been completely removed from childhood vaccines in many countries, including our country. However, some vaccines in use in the United States and developing countries still contain thiomersal. Although many regulatory organizations have repeatedly stated that amount of mercury exposure by vaccines is very low and will not cause any pathological conditions, vaccine hesitancy is gradually increasing due to speculations about thiomersal. However, vaccination is absolutely neccesary to protect public health. Avoiding childhood vaccination due to unascertained or non-existant relationship puts the whole population under great risk. In this review, we aimed to give information about autism, thiomersal and possible connection between thiomersal and autism.

Keywords: Autism; thiomersal; vaccine; vaccine hesitancy
REFERENCES:
  1. Karimi P, Kamali E, Mousavi SM, Karahmadi M. Environmental factors influencing the risk of autism. J Res Med Sci. 2017;22:27.[Crossref] [PubMed] [PMC] 
  2. Ergaz Z, Weinstein-Fudim L, Ornoy A. Genetic and non-genetic animal models for autism spectrum disorders (ASD). Reprod Toxicol. 2016;64:116-40.[Crossref] [PubMed] 
  3. American Psychiatric Association. The Diagnostic and Statistical Manual of Mental Disorders: DSM 5. 5th ed. Arlington, VA: Bookpoint; 2013.[Link] 
  4. Kern JK, Geier DA, Sykes LK, Haley BE, Geier MR. The relationship between mercury and autism: A comprehensive review and discussion. J Trace Elem Med Biol. 2016;37:8-24.[Crossref] [PubMed] 
  5. Laurence JA, Fatemi SH. Glial fibrillary acidic protein is elevated in superior frontal, parietal and cerebellar cortices of autistic subjects. Cerebellum. 2005;4(3):206-10.[Crossref] [PubMed] 
  6. Tetreault NA, Hakeem AY, Jiang S, Williams BA, Allman E, Wold BJ, et al. Microglia in the cerebral cortex in autism. J Autism Dev Disord. 2012;42(12):2569-84.[Crossref] [PubMed] 
  7. Li X, Chauhan A, Sheikh AM, Patil S, Chauhan V, Li XM, et al. Elevated immune response in the brain of autistic patients. J Neuroimmunol. 2009;207(1-2):111-6.[Crossref] [PubMed] [PMC] 
  8. Rodriguez JI, Kern JK. Evidence of microglial activation in autism and its possible role in brain underconnectivity. Neuron Glia Biol. 2011;7(2-4):205-13.[Crossref] [PubMed] [PMC] 
  9. Ornoy A, Weinstein-Fudim L, Ergaz Z. Prenatal factors associated with autism spectrum disorder (ASD). Reprod Toxicol. 2015;56:155-69.[Crossref] [PubMed] 
  10. Bridgemohan C, Cochran DM, Howe YJ, Pawlowski K, Zimmerman AW, Anderson GM, et al. Investigating Potential Biomarkers in Autism Spectrum Disorder. Front Integr Neurosci. 2019;13:31.[Crossref] [PubMed] [PMC] 
  11. Wang L, Angley MT, Gerber JP, Sorich MJ. A review of candidate urinary biomarkers for autism spectrum disorder. Biomarkers. 2011;16(7):537-52.[Crossref] [PubMed] 
  12. Tordjman S, Anderson GM, Bellissant E, Botbol M, Charbuy H, Camus F, et al. Day and nighttime excretion of 6-sulphatoxymelatonin in adolescents and young adults with autistic disorder. Psychoneuroendocrinology. 2012;37(12):1990-7.[Crossref] [PubMed] 
  13. Gabriele S, Sacco R, Persico AM. Blood serotonin levels in autism spectrum disorder: a systematic review and meta-analysis. Eur Neuropsychopharmacol. 2014;24(6):919-29.[Crossref] [PubMed] 
  14. Hammock E, Veenstra-VanderWeele J, Yan Z, Kerr TM, Morris M, Anderson GM, et al. Examining autism spectrum disorders by biomarkers: example from the oxytocin and serotonin systems. J Am Acad Child Adolesc Psychiatry. 2012;51(7):712-21.e1.Erratum in: J Am Acad Child Adolesc Psychiatry. 2012;51(8):851.[Crossref] [PubMed] [PMC] 
  15. Pagan C, Delorme R, Callebert J, Goubran-Botros H, Amsellem F, Drouot X, et al. The serotonin-N-acetylserotonin-melatonin pathway as a biomarker for autism spectrum disorders. Transl Psychiatry. 2014;4(11):e479.[Crossref] [PubMed] [PMC] 
  16. Mulder EJ, Anderson GM, Kemperman RF, Oosterloo-Duinkerken A, Minderaa RB, Kema IP. Urinary excretion of 5-hydroxyindoleacetic acid, serotonin and 6-sulphatoxymelatonin in normoserotonemic and hyperserotonemic autistic individuals. Neuropsychobiology. 2010;61(1):27-32.[Crossref] [PubMed] 
  17. Kolevzon A, Newcorn JH, Kryzak L, Chaplin W, Watner D, Hollander E, et al. Relationship between whole blood serotonin and repetitive behaviors in autism. Psychiatry Res. 2010;175(3):274-6.[Crossref] [PubMed] [PMC] 
  18. Sacco R, Militerni R, Frolli A, Bravaccio C, Gritti A, Elia M, et al. Clinical, morphological, and biochemical correlates of head circumference in autism. Biol Psychiatry. 2007;62(9):1038-47.[Crossref] [PubMed] 
  19. Schaefer GB, Mendelsohn NJ; Professional Practice and Guidelines Committee. Clinical genetics evaluation in identifying the etiology of autism spectrum disorders. Genet Med. 2008;10(4):301-5.[Crossref] [PubMed] [PMC] 
  20. Miller DT, Adam MP, Aradhya S, Biesecker LG, Brothman AR, Carter NP, et al. Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. Am J Hum Genet. 2010;86(5):749-64.[Crossref] [PubMed] [PMC] 
  21. Hönekopp J. Digit ratio 2D:4D in relation to autism spectrum disorders, empathizing, and systemizing: a quantitative review. Autism Res. 2012;5(4):221-30.[Crossref] [PubMed] 
  22. Aldinger KA, Lane CJ, Veenstra-VanderWeele J, Levitt P. Patterns of Risk for Multiple Co-Occurring Medical Conditions Replicate Across Distinct Cohorts of Children with Autism Spectrum Disorder. Autism Res. 2015;8(6):771-81.[Crossref] [PubMed] [PMC] 
  23. Sealey LA, Hughes BW, Sriskanda AN, Guest JR, Gibson AD, Johnson-Williams L, et al. Environmental factors in the development of autism spectrum disorders. Environ Int. 2016;88:288-98.[Crossref] [PubMed] 
  24. Weiss LA, Arking DE; Gene Discovery Project of Johns Hopkins & the Autism Consortium, Daly MJ, Chakravarti A. A genome-wide linkage and association scan reveals novel loci for autism. Nature. 2009;461(7265):802-8.[Crossref] [PubMed] [PMC] 
  25. Nguyen A, Rauch TA, Pfeifer GP, Hu VW. Global methylation profiling of lymphoblastoid cell lines reveals epigenetic contributions to autism spectrum disorders and a novel autism candidate gene, RORA, whose protein product is reduced in autistic brain. FASEB J. 2010;24(8):3036-51.[Crossref] [PubMed] [PMC] 
  26. Landrigan PJ, Lambertini L, Birnbaum LS. A research strategy to discover the environmental causes of autism and neurodevelopmental disabilities. Environ Health Perspect. 2012;120(7):a258-60.[Crossref] [PubMed] [PMC] 
  27. Shen Y, Dies KA, Holm IA, Bridgemohan C, Sobeih MM, Caronna EB, et al. Autism Consortium Clinical Genetics/DNA Diagnostics Collaboration. Clinical genetic testing for patients with autism spectrum disorders. Pediatrics. 2010;125(4):e727-35.[Crossref] [PubMed] [PMC] 
  28. Hallmayer J, Cleveland S, Torres A, Phillips J, Cohen B, Torigoe T, et al. Genetic heritability and shared environmental factors among twin pairs with autism. Arch Gen Psychiatry. 2011;68(11):1095-102.[Crossref] [PubMed] [PMC] 
  29. Geschwind DH. Genetics of autism spectrum disorders. Trends Cogn Sci. 2011;15(9):409-16.[Crossref] [PubMed] [PMC] 
  30. Perera F, Herbstman J. Prenatal environmental exposures, epigenetics, and disease. Reprod Toxicol. 2011;31(3):363-73.[Crossref] [PubMed] [PMC] 
  31. Wang SC, Oelze B, Schumacher A. Age-specific epigenetic drift in late-onset Alzheimer's disease. PLoS One. 2008;3(7):e2698.[Crossref] [PubMed] [PMC] 
  32. Grandjean P, Landrigan PJ. Developmental neurotoxicity of industrial chemicals. Lancet. 2006;368(9553):2167-78.[Crossref] [PubMed] 
  33. Clarkson TW, Magos L. The toxicology of mercury and its chemical compounds. Crit Rev Toxicol. 2006;36(8):609-62.[Crossref] [PubMed] 
  34. Dórea JG, Farina M, Rocha JB. Toxicity of ethylmercury (and Thimerosal): a comparison with methylmercury. J Appl Toxicol. 2013;33(8):700-11.[Crossref] [PubMed] 
  35. Smithburn KC, Kempf GE, Zerfas LG, Gilman LH. Meningococcic meningitis: a clinical study of one hundred and forty-four cases. JAMA. 1930;95(11):776-80.[Crossref] 
  36. Stetler HC, Garbe PL, Dwyer DM, Facklam RR, Orenstein WA, West GR, et al. Outbreaks of group A streptococcal abscesses following diphtheria-tetanus toxoid-pertussis vaccination. Pediatrics. 1985;75(2):299-303.[PubMed] 
  37. Khandke L, Yang C, Krylova K, Jansen KU, Rashidbaigi A. Preservative of choice for Prev(e)nar 13? in a multi-dose formulation. Vaccine. 2011;29(41):7144-53.[Crossref] [PubMed] 
  38. Uchida T, Naito S, Kato H, Hatano I, Harashima A, Terada Y, et al. Thimerosal induces toxic reaction in non-sensitized animals. Int Arch Allergy Immunol. 1994;104(3):296-301.[Crossref] [PubMed] 
  39. Gama Ker H, Dian de Oliveira Aguiar-Soares R, Mendes Roatt B, das Dores Moreira N, Coura-Vital W, Martins Carneiro C, et al. Effect of the preservative and temperature conditions on the stability of Leishmania infantum promastigotes antigens applied in a flow cytometry diagnostic method for canine visceral leishmaniasis. Diagn Microbiol Infect Dis. 2013;76(4):470-6.[Crossref] [PubMed] 
  40. Mason JM, Osborne PT, Hall AJ, Skolnik JS, Woods LL, Wood CL, et al. Example of a thimerosal-dependent antibody without apparent blood group specificity. Vox Sang. 1985;48(5):313-6.[Crossref] [PubMed] 
  41. Towne V, Oswald CB, Mogg R, Antonello J, Will M, Gimenez J, et al. Measurement and decomposition kinetics of residual hydrogen peroxide in the presence of commonly used excipients and preservatives. J Pharm Sci. 2009;98(11):3987-96.[Crossref] [PubMed] 
  42. Centers for Disease Control and Prevention (CDC). Thimerosal in vaccines: a joint statement of the American Academy of Pediatrics and the Public Health Service. MMWR Morb Mortal Wkly Rep. 1999;48(26):563-5.[PubMed] 
  43. Thimerosal in vaccines--An interim report to clinicians. American Academy of Pediatrics. Committee on Infectious Diseases and Committee on Environmental Health. Pediatrics. 1999;104(3 Pt 1):570-4.[Crossref] [PubMed] 
  44. Hurley AM, Tadrous M, Miller ES. Thimerosal-containing vaccines and autism: a review of recent epidemiologic studies. J Pediatr Pharmacol Ther. 2010;15(3):173-81.[Crossref] [PubMed] [PMC] 
  45. TC Sağlık Bakanlığı. Aşı Portalı. Aşı İçerikleri. 2018. (Erişim Tarihi: 19.09.2019)[Link] 
  46. Bigham M, Copes R. Thiomersal in vaccines: balancing the risk of adverse effects with the risk of vaccine-preventable disease. Drug Saf. 2005;28(2):89-101.[Crossref] [PubMed] 
  47. Madsen KM, Hviid A, Vestergaard M, Schendel D, Wohlfahrt J, Thorsen P, et al. A population-based study of measles, mumps, and rubella vaccination and autism. N Engl J Med. 2002;347(19):1477-82.[Crossref] [PubMed] 
  48. Andrews N, Miller E, Grant A, Stowe J, Osborne V, Taylor B. Thimerosal exposure in infants and developmental disorders: a retrospective cohort study in the United kingdom does not support a causal association. Pediatrics. 2004;114(3):584-91.[Crossref] [PubMed] 
  49. Verstraeten T, Davis RL, DeStefano F, Lieu TA, Rhodes PH, Black SB, et al; Vaccine Safety Datalink Team. Safety of thimerosal-containing vaccines: a two-phased study of computerized health maintenance organization databases. Pediatrics. 2003;112(5):1039-48. Erratum in: Pediatrics. 2004;113(1):184.[PubMed] 
  50. World Health Organization. Global Advisory Committee on Vaccine Safety, 2006.Erişim Tarihi: 11.12.2019.[Link] 
  51. Institute of Medicine (US) Immunization Safety Review Committee. Immunization Safety Review: Thimerosal-Containing Vaccines and Neurodevelopmental Disorders. Stratton K, Gable A, McCormick MC, eds. Washington (DC): National Academies Press (US);2001.[PubMed] 
  52. Landrigan PJ, Kimmel CA, Correa A, Eskenazi B. Children's health and the environment: public health issues and challenges for risk assessment. Environ Health Perspect. 2004;112(2):257-65.[Crossref] [PubMed] [PMC] 
  53. Cinca I, Dumitrescu I, Onaca P, Serbänescu A, Nestorescu B. Accidental ethyl mercury poisoning with nervous system, skeletal muscle, and myocardium injury. J Neurol Neurosurg Psychiatry. 1980;43(2):143-9.[Crossref] [PubMed] [PMC] 
  54. Jafari T, Rostampour N, Fallah AA, Hesami A. The association between mercury levels and autism spectrum disorders: A systematic review and meta-analysis. J Trace Elem Med Biol. 2017;44:289-297.[Crossref] [PubMed] 
  55. Holmes AS, Blaxill MF, Haley BE. Reduced levels of mercury in first baby haircuts of autistic children. Int J Toxicol. 2003;22(4):277-85.[Crossref] [PubMed] 
  56. Wakefield AJ, Murch SH, Anthony A, Linnell J, Casson DM, Malik M, et al. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet. 1998;351(9103):637-41. Retraction in: Lancet. 2010;375(9713):445. Erratum in: Lancet. 2004;363(9411):750.[Crossref] [PubMed] 
  57. Newschaffer CJ, Fallin D, Lee NL. Heritable and nonheritable risk factors for autism spectrum disorders. Epidemiol Rev. 2002;24(2):137-53.[Crossref] [PubMed] 
  58. Grønborg TK, Schendel DE, Parner ET. Recurrence of autism spectrum disorders in full- and half-siblings and trends over time: a population-based cohort study. JAMA Pediatr. 2013;167(10):947-53.[Crossref] [PubMed] [PMC] 
  59. Tomljenovic L, Shaw CA. "One-size fits all"? Vaccine. 2012;30(12):2040.[Crossref] [PubMed] 
  60. Dórea JG. Abating Mercury Exposure in Young Children Should Include Thimerosal-Free Vaccines. Neurochem Res. 2017;42(10):2673-85.[Crossref] [PubMed] 
  61. Geier DA, Kern JK, King PG, Sykes LK, Geier MR. The risk of neurodevelopmental disorders following a thimerosal-preserved DTaP formulation in comparison to its thimerosal-reduced formulation in the Vaccine Adverse Event Reporting System (VAERS). J Biochem Pharmacol Res. 2014;2(2):64-73.[Link] 
  62. Dórea JG. Making sense of epidemiological studies of young children exposed to thimerosal in vaccines. Clin Chim Acta. 2010;411(21-2):1580-6.[Crossref] [PubMed] 
  63. Thompson WW, Price C, Goodson B, Shay DK, Benson P, Hinrichsen VL, et al. Vaccine Safety Datalink Team. Early thimerosal exposure and neuropsychological outcomes at 7 to 10 years. N Engl J Med. 2007;357(13):1281-92.[Crossref] [PubMed] 
  64. Uno Y, Uchiyama T, Kurosawa M, Aleksic B, Ozaki N. Early exposure to the combined measles-mumps-rubella vaccine and thimerosal-containing vaccines and risk of autism spectrum disorder. Vaccine. 2015;33(21):2511-6.[Crossref] [PubMed] 
  65. Yoshimasu K, Kiyohara C, Takemura S, Nakai K. A meta-analysis of the evidence on the impact of prenatal and early infancy exposures to mercury on autism and attention deficit/hyperactivity disorder in the childhood. Neurotoxicology. 2014;44:121-31.[Crossref] [PubMed] 
  66. Young HA, Geier DA, Geier MR. Thimerosal exposure in infants and neurodevelopmental disorders: an assessment of computerized medical records in the Vaccine Safety Datalink. J Neurol Sci. 2008;271(1-2):110-8.[Crossref] [PubMed] 
  67. Gallagher CM, Goodman MS. Hepatitis B vaccination of male neonates and autism diagnosis, NHIS 1997-2002. J Toxicol Environ Health A. 2010;73(24):1665-77.[Crossref] [PubMed] 
  68. Geier DA, Mumper E, Gladfelter B, Coleman L, Geier MR. Neurodevelopmental disorders, maternal Rh-negativity, and Rho(D) immune globulins: a multi-center assessment. Neuro Endocrinol Lett. 2008;29(2):272-80.[PubMed] 
  69. Geier DA, Geier MR. A case series of children with apparent mercury toxic encephalopathies manifesting with clinical symptoms of regressive autistic disorders. J Toxicol Environ Health A. 2007;70(10):837-51.[Crossref] [PubMed] 
  70. Fagan DG, Pritchard JS, Clarkson TW, Greenwood MR. Organ mercury levels in infants with omphaloceles treated with organic mercurial antiseptic. Arch Dis Child. 1977;52(12):962-4.[Crossref] [PubMed] [PMC] 
  71. Mutter J, Naumann J, Schneider R, Walach H, Haley B. Mercury and autism: accelerating evidence? Neuro Endocrinol Lett. 2005;26(5):439-46.[PubMed] 
  72. Burbacher TM, Shen DD, Liberato N, Grant KS, Cernichiari E, Clarkson T. Comparison of blood and brain mercury levels in infant monkeys exposed to methylmercury or vaccines containing thimerosal. Environ Health Perspect. 2005;113(8):1015-21.[Crossref] [PubMed] [PMC] 
  73. Gadad BS, Li W, Yazdani U, Grady S, Johnson T, Hammond J, et al. Administration of thimerosal-containing vaccines to infant rhesus macaques does not result in autism-like behavior or neuropathology. Proc Natl Acad Sci U S A. 2015;112(40):12498-503.[Crossref] [PubMed] [PMC] 
  74. Namvarpour Z, AminiA, Nasehi M, Zarrindast MR. The Effects of Early Exposure to Thimerosal on Impairments of Social and Stereotyped Behaviors and the Number of Purkinje Cells of Cerebellum in Rats. J Appl Biotechnol Rep. 2018;5(3):105-11.[Crossref] 
  75. Rose S, Wynne R, Frye RE, Melnyk S, James SJ. Increased susceptibility to ethylmercury-induced mitochondrial dysfunction in a subset of autism lymphoblastoid cell lines. J Toxicol. 2015;2015:573701.[Crossref] [PubMed] [PMC] 

.: Up To Date

Login

 Forgot your password?

 New Registration  

Contact

Ortadoğu Reklam Tanıtım Yayıncılık Turizm Eğitim İnşaat Sanayi ve Ticaret A.Ş.

.: Address

Turkocagi Caddesi No:30 06520 Balgat / ANKARA
Phone: +90 312 286 56 56
Fax: +90 312 220 04 70
E-mail: info@turkiyeklinikleri.com

.: Manuscript Editing Department

Phone: +90 312 286 56 56/ 2
E-mail: yaziisleri@turkiyeklinikleri.com

.: English Language Redaction

Phone: +90 312 286 56 56/ 145
E-mail: tkyayindestek@turkiyeklinikleri.com

.: Marketing Sales-Project Department

Phone: +90 312 286 56 56/ 142
E-mail: reklam@turkiyeklinikleri.com

.: Subscription and Public Relations Department

Phone: +90 312 286 56 56/ 118
E-mail: abone@turkiyeklinikleri.com

.: Customer Services

Phone: +90 312 286 56 56/ 118
E-mail: satisdestek@turkiyeklinikleri.com

1. TERMS OF USE

1.1. To use the web pages with http://www.turkiyeklinikleri.com domain name or the websites reached through the sub domain names attached to the domain name (They will be collectively referred as "SITE"), please read the conditions below. If you do not accept these terms, please cease to use the "SITE." "SITE" owner reserves the right to change the information on the website, forms, contents, the "SITE," "SITE" terms of use anytime they want.

1.2. The owner of the "SITE" is Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. (From now on it is going to be referred as "Turkiye Klinikleri", shortly) and it resides at Turkocagi cad. No:30, 06520 Balgat Ankara. The services in the "SITE" are provided by "Turkiye Klinikleri."

1.3. Anyone accessing the "SITE" with or without a fee whether they are a natural person or a legal identity is considered to agree these terms of use. In this contract hereby, "Turkiye Klinikleri" may change the stated terms anytime. These changes will be published in the "SITE" periodically and they will be valid when they are published. Any natural person or legal identity benefiting from and reaching to the "SITE" are considered to be agreed to any change on hereby contract terms done by "Turkiye Klinikleri."

1.4. The "Terms of Use" hereby is published in the website with the last change on March 30th 2014 and the "SITE" is activated by enabling the access to everyone. The "Terms of Use" hereby is also a part of the any "USER Contract" was and/or will be done with the users using "Turkiye Klinikleri" services with or without a fee an inseparable.

2. DEFINITIONS

2.1. "SITE": A website offering different kind of services and context with a certain frame determined by "Turkiye Klinikleri" and it is accessible on-line on http://www.turkiyeklinikleri.com domain name and/or subdomains connected to the domain name.

2.2. USER: A natural person or a legal identity accessing to the "SITE" through online settings.

2.3. LINK: A link enabling to access to another website through the "SITE", the files, the context or through another website to the "SITE", the files and the context.

2.4. CONTEXT: Any visual, literary and auditory images published in the "Turkiye Klinikleri", "SITE" and/or any website or any accessible information, file, picture, number/figures, price, etc.

2.5. "USER CONTRACT": An electronically signed contract between a natural or a legal identity benefiting from special services "Turkiye Klinikleri" will provide and "Turkiye Klinikleri".

3. SCOPE OF THE SERVICES

3.1. "Turkiye Klinikleri" is completely free to determine the scope and quality of the services via the "SITE".

3.2. To benefit the services of "Turkiye Klinikleri" "SITE", the "USER" must deliver the features that will be specified by "Turkiye Klinikleri". "Turkiye Klinikleri" may change this necessity any time single-sided.

3.3. Not for a limited number, the services "Turkiye Klinikleri" will provide through the "SITE" for a certain price or for free are;

- Providing scientific articles, books and informative publications for health industry.

- Providing structural, statistical and editorial support to article preparation stage for scientific journals.

4. GENERAL PROVISIONS

4.1. "Turkiye Klinikleri" is completely free to determine which of the services and contents provided in the "SITE" will be charged.

4.2. People benefiting from the services provided by "Turkiye Klinikleri" and using the website can use the "SITE" only according to the law and only for personal reasons. Users have the criminal and civil liability for every process and action they take in the "SITE". Every USER agrees, declares and undertakes that they will not proceed by any function or action infringement of rights of "Turkiye Klinikleri"s and/or other third parties', they are the exclusive right holder on usage, processing, storage, made public and revealing any written, visual or auditory information reported to Turkiye Klinikleri" and/or "SITE" to the third parties. "USER" agrees and undertakes that s/he will not duplicate, copy, distribute, process, the pictures, text, visual and auditory images, video clips, files, databases, catalogs and lists within the "SITE", s/he will not be using these actions or with other ways to compete with "Turkiye Klinikleri", directly or indirectly.

4.3. The services provided and the context published within the "SITE" by third parties is not under the responsibility of "Turkiye Klinikleri", institutions collaborated with "Turkiye Klinikleri", "Turkiye Klinikleri" employee and directors, "Turkiye Klinikleri" authorized salespeople. Commitment to accuracy and legality of the published information, context, visual and auditory images provided by any third party are under the full responsibility of the third party. "Turkiye Klinikleri" does not promise and guarantee the safety, accuracy and legality of the services and context provided by a third party.

4.4. "USER"s cannot act against "Turkiye Klinikleri", other "USER"s and third parties by using the "SITE". "Turkiye Klinikleri" has no direct and/or indirect responsibility for any damage a third party suffered or will suffer regarding "USER"s actions on the "SITE" against the rules of the hereby "Terms of Use" and the law.

4.5. "USER"s accept and undertake that the information and context they provided to the "SITE" are accurate and legal. "Turkiye Klinikleri" is not liable and responsible for promising and guaranteeing the verification of the information and context transmitted to "Turkiye Klinikleri" by the "USER"s, or uploaded, changed and provided through the "SITE" by them and whether these information are safe, accurate and legal.

4.6. "USER"s agree and undertake that they will not perform any action leading to unfair competition, weakening the personal and commercial credit of "Turkiye Klinikleri" and a third party,  encroaching and attacking on personal rights within the "SITE" in accordance with the Turkish Commercial Code Law.

4.7. "Turkiye Klinikleri" reserves the right to change the services and the context within the "SITE"  anytime. "Turkiye Klinikleri" may use this right without any notification and timelessly. "USER"s have to make the changes and/or corrections "Turkiye Klinikleri" required immediately. Any changes and/or corrections that are required by "Turkiye Klinikleri", may be made by "Turkiye Klinikleri" when needed. Any harm, criminal and civil liability resulted or will result from changes and/or corrections required by "Turkiye Klinikleri" and were not made on time by the "USER"s belongs completely to the users.

4.8. "Turkiye Klinikleri" may give links through the "SITE" to other websites and/or "CONTEXT"s and/or folders that are outside of their control and owned and run by third parties. These links are provided for ease of reference only and do not hold qualification for support the respective web SITE or the admin or declaration or guarantee for the information inside. "Turkiye Klinikleri" does not hold any responsibility over the web-sites connected through the links on the "SITE", folders and context, the services or products on the websites provided through these links or their context.

4.9. "Turkiye Klinikleri" may use the information provided to them by the "USERS" through the "SITE" in line with the terms of the "PRIVACY POLICY" and "USER CONTRACT". It may process the information or classify and save them on a database. "Turkiye Klinikleri" may also use the USER's or visitor's identity, address, e-mail address, phone number, IP number, which sections of the "SITE" they visited, domain type, browser type, date and time information to provide statistical evaluation and customized services.

5. PROPRIETARY RIGHTS

5.1. The information accessed through this "SITE" or provided by the users legally and all the elements (including but not limited to design, text, image, html code and other codes) of the "SITE" (all of them will be called as studies tied to "Turkiye Klinikleri"s copyrights) belongs to "Turkiye Klinikleri". Users do not have the right to resell, process, share, distribute, display or give someone permission to access or to use the "Turkiye Klinikleri" services, "Turkiye Klinikleri" information and the products under copyright protection by "Turkiye Klinikleri". Within hereby "Terms of Use" unless explicitly permitted by "Turkiye Klinikleri" nobody can reproduce, process, distribute or produce or prepare any study from those under "Turkiye Klinikleri" copyright protection.

5.2. Within hereby "Terms of Use", "Turkiye Klinikleri" reserves the rights for "Turkiye Klinikleri" services, "Turkiye Klinikleri" information, the products associated with "Turkiye Klinikleri" copyrights, "Turkiye Klinikleri" trademarks, "Turkiye Klinikleri" trade looks or its all rights for other entity and information it has through this website unless it is explicitly authorized by "Turkiye Klinikleri".

6. CHANGES IN THE TERMS OF USE

"Turkiye Klinikleri" in its sole discretion may change the hereby "Terms of Use" anytime announcing within the "SITE". The changed terms of the hereby "Terms of Use" will become valid when they are announced. Hereby "Terms of Use" cannot be changed by unilateral declarations of users.

7. FORCE MAJEURE

"Turkiye Klinikleri" is not responsible for executing late or never of this hereby "Terms of Use", privacy policy and "USER Contract" in any situation legally taken into account as force majeure. Being late or failure of performance or non-defaulting of this and similar cases like this will not be the case from the viewpoint of "Turkiye Klinikleri", and "Turkiye Klinikleri" will not have any damage liability for these situations. "Force majeure" term will be regarded as outside of the concerned party's reasonable control and any situation that "Turkiye Klinikleri" cannot prevent even though it shows due diligence. Also, force majeure situations include but not limited to natural disasters, rebellion, war, strike, communication problems, infrastructure and internet failure, power cut and bad weather conditions.

8. LAW AND AUTHORISATION TO FOLLOW

Turkish Law will be applied in practicing, interpreting the hereby "Terms of Use" and managing the emerging legal relationships within this "Terms of Use" in case of finding element of foreignness, except for the rules of Turkish conflict of laws. Ankara Courts and Enforcement Offices are entitled in any controversy happened or may happen due to hereby contract.

9. CLOSING AND AGREEMENT

Hereby "Terms of Use" come into force when announced in the "SITE" by "Turkiye Klinikleri". The users are regarded to agree to hereby contract terms by using the "SITE". "Turkiye Klinikleri" may change the contract terms and the changes will be come into force by specifying the version number and the date of change on time it is published in the "SITE".

 

30.03.2014

Privacy Policy

We recommend you to read the terms of use below before you visit our website. In case you agree these terms, following our rules will be to your favor. Please read our Terms of Use thoroughly.

www.turkiyeklinikleri.com website belongs to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. and is designed in order to inform physicians in the field of health

www.turkiyeklinikleri.com cannot reach to user’s identity, address, service providers or other information. The users may send this information to the website through forms if they would like to. However, www.turkiyeklinikleri.com may collect your hardware and software information. The information consists of your IP address, browser type, operating system, domain name, access time, and related websites. www.turkiyeklinikleri.com cannot sell the provided user information (your name, e-mail address, home and work address, phone number) to the third parties, publish it publicly, or keep it in the website. Gathered information has a directing feature to be a source for the website’s visitor profile, reporting and promotion of the services.

www.turkiyeklinikleri.com uses the taken information:

-To enhance, improve and maintain the quality of the website

-To generate visitor’s profile and statistical data

-To determine the tendency of the visitors on using our website

-To send print publications/correspondences

-To send press releases or notifications through e-mail

-To generate a list for an event or competition

By using www.turkiyeklinikleri.com you are considered to agree that;

-Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. cannot be hold responsible for any user’s illegal and immoral behavior,

-Terms of use may change from time to time,

-It is not responsible for other websites’ contents it cannot control or the harms they may cause although it uses the connection they provided.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. may block the website to users in the following events:

-Information with wrong, incomplete, deceiving or immoral expressions is recorded to the website,

-Proclamation, advertisement, announcement, libelous expressions are used against natural person or legal identity,

-During various attacks to the website,

-Disruption of the website because of a virus.

Written, visual and audible materials of the website, including the code and the software are under protection by legal legislation.

Without the written consent of Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. the information on the website cannot be downloaded, changed, reproduced, copied, republished, posted or distributed.

All rights of the software and the design of the website belong to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. will be pleased to hear your comments about our terms of use. Please share the subjects you think may enrich our website or if there is any problem regarding our website.

info@turkiyeklinikleri.com